• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.26% Nasdaq Down0.34%

    Revance Therapeutics, Inc. (RVNC)

    31.60 Up 0.12(0.38%) 4:00PM EDT
    |After Hours : 31.55 Down 0.05 (0.16%) 4:49PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Revance Therapeutics, Inc.
    7555 Gateway Boulevard
    Newark, CA 94560
    United States - Map
    Phone: 510-742-3400
    Website: http://www.revance.com

    Index Membership:N/A
    Full Time Employees:86

    Business Summary 

    Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. It develops RT001, a topical gel formulation of botulinum toxin type A that is in Phase III development program for the treatment of crow’s feet lines in North America and is initiating a Phase II clinical trial for the treatment of primary axillary, or underarm, hyperhidrosis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is in a Phase II active comparator clinical trial for the treatment of glabellar lines and is initiating a Phase II trial for the treatment of cervical dystonia. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Revance Therapeutics, Inc.

    Corporate Governance 
    Revance Therapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. L. Daniel Browne , 53
    Founder, Chief Exec. Officer, Pres and Director
    Dr. Jacob Waugh M.D., 44
    Co-Founder and Chief Scientific Officer
    Dr. Arthur Peter Bertolino M.D., Ph.D., MBA, 60
    Chief Medical Officer and Exec. VP
    Mrs. Lauren P. Silvernail , 56
    Chief Financial Officer, Principal Financial & Accounting Officer, Exec. VP of Corp. Devel. and Sec.
    Jeanie D. Herbert ,
    Sr. Director of Investor Relations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders